GTx, Inc. Announces Presentation Of Preclinical Data Demonstrating The Ability Of Sards To Degrade And Inhibit The Androgen Receptor At The American Urological Association Annual Meeting

MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) today announced the first public presentation of preclinical data from the Company’s selective androgen receptor degrader (SARD) program. The results demonstrate that the Company’s highly potent SARDs selectively bind to the ligand binding domain (LBD) and interact with the N-terminal domain (NTD) of the androgen receptor (AR) and inhibit and degrade the AR at very low concentrations. These preclinical results suggest that the Company’s SARDs may be the first-in-class dual-interacting AR antagonists and degraders.